Atrial and B-Type Natriuretic Peptides

Introduction

• ANP and BNP are endogenous hormones essential for cardiovascular and renal homeostasis. These peptides are produced in response to myocardial stretch and serve as counter-regulatory mediators that oppose volume overload, vasoconstriction, and neurohormonal activation.
• Their release represents a key compensatory response in states of increased intracardiac pressure, such as heart failure.¹

Sites of Production

• ANP is synthesized and stored in granules within atrial myocytes.¹
• BNP is predominantly produced by ventricular myocytes, particularly during chronic pressure or volume overload.²
• NT-proBNP is released in equimolar amounts to BNP and has a longer half-life, improving its clinical utility.³

Stimuli for Release

ANP and BNP secretion is stimulated by:

• Atrial or ventricular stretch
• Volume overload (i.e., elevated end-diastolic pressures)
• Endothelin
• Hypoxia
• Thyroid hormones
• Antithrombin II
• Sympathetic activation and renin-angiotensin-aldosterone-system stimulation^2,3

Receptor Signaling

• The primary receptor for ANP and BNP is natriuretic peptide receptor-A (NPR-A).¹
• NPR-A activation increases cGMP, resulting in smooth muscle relaxation, natriuresis, and diuresis.¹
• Circulating levels are regulated by neprilysin degradation and binding to clearance receptors (NPR-C).^1,2

Cardiovascular and Renal Effects

Hemodynamic Effects

• ANP and BNP produce balanced vasodilation, reducing both preload and afterload.
  • Systemic vascular resistance is decreased via cGMP-mediated relaxation of vascular smooth muscle.¹
  • Venous dilation reduces venous return and decreases cardiac filling pressures, hence reducing preload.³
  • Pulmonary vascular resistance is lowered, improving right ventricular unloading.²
• These actions enhance cardiac output in states of fluid overload or ventricular dysfunction.

Renal Effects

• ANP and BNP promote natriuresis and diuresis through several complementary mechanisms:
  • Glomerular filtration rate increases due to afferent arteriolar dilation and efferent constriction.²
  • Collecting duct sodium reabsorption is inhibited, promoting natriuresis.²
  • Renal sympathetic activity is reduced, improving renal blood flow.²
• These effects counteract fluid retention and help regulate intravascular volume.

Neurohormonal Modulation

• The natriuretic peptides exert inhibitory effects on multiple vasoconstrictive and sodium-retaining systems:
  • Renin release is suppressed, reducing angiotensin II and aldosterone activity.³
  • Sympathetic tone and norepinephrine release are decreased.³
  • Endothelin secretion is inhibited.¹
• This neurohormonal balance is crucial in heart failure, where ANP and BNP provide protective counter-regulation.

Clinical and Perioperative Applications

Diagnostic Use in Heart Failure

• BNP and NT-proBNP are well-established biomarkers for diagnosing and assessing heart failure.
  • Elevated levels correlate with increased ventricular filling pressures and reduced systolic or diastolic function.³
  • BNP rises quickly during acute decompensation and falls with appropriate therapy.³
  • NT-proBNP, with a longer half-life, offers improved diagnostic stability in chronic disease.³

Diagnostic Applications

• BNP and NT-proBNP are widely used to diagnose and evaluate heart failure in both ambulatory and acute care settings.
  • BNP values greater than 100 pg/mL or NT-proBNP values above 300 pg/mL strongly suggest acute decompensated heart failure, while lower values carry a high negative predictive value.
  • Age-adjusted NT-proBNP thresholds improve diagnostic accuracy: more than 450 pg/mL for patients younger than 50 years, more than 900 pg/mL for those between 50 and 75 years, and more than1800 pg/mL for patients older than 75 years.
  • Interpretation should consider the clinical context, as elevations may occur in renal dysfunction, pulmonary hypertension, atrial fibrillation, sepsis, and advanced age. Conversely, obesity is associated with lower BNP concentrations and may obscure the presence of heart failure.

Risk Stratification

• Preoperative BNP and NT-proBNP strongly predict postoperative cardiac complications.
  • Elevated levels are associated with increased risk of myocardial injury, heart failure exacerbation, arrhythmias, and mortality.⁴
  • NT-proBNP thresholds (e.g., >300 pg/mL) have been used to identify patients at higher risk.⁵
  • Persistent postoperative elevation may indicate ongoing myocardial stress, and mid-regional pro-ANP (MR-proANP) has emerged as an additional biomarker with improved stability for evaluating heart failure.⁴

Perioperative Anesthetic Considerations

• BNP and NT-proBNP measurements can guide preoperative optimization and perioperative planning.
  • Elevated values may support the use of invasive monitoring, cautious fluid administration, and planned postoperative observation.⁴
  • Rising levels can help distinguish cardiogenic from pulmonary causes of dyspnea in the perioperative period.⁴
  • BNP-guided risk stratification is particularly useful when echocardiographic data are unavailable or outdated.⁴

Therapeutic Considerations

• Pharmacologic modulation of the natriuretic peptide system highlights the physiologic relevance of ANP and BNP.
• ANP is approximately 10 times more potent than BNP in stimulating natriuresis and vasodilation, but its clinical measurement is limited because it is rapidly cleared and has a much shorter half-life.
• Recombinant BNP (nesiritide) promotes vasodilation and natriuresis, although routine use has declined.³
• Neprilysin inhibitors (e.g., sacubitril/valsartan) enhance endogenous natriuretic peptide activity by reducing peptide degradation.^1,2
• These therapies emphasize the clinical importance of this hormonal pathway in acute and chronic cardiac disease.

Therapeutic Applications and Drug Development

• Therapies targeting natriuretic peptide pathways aim to enhance the beneficial effects of ANP and BNP on cardiovascular and renal function.⁶
• Recombinant BNP (nesiritide) has been used in acute decompensated heart failure, although routine use has decreased due to limited outcome benefits and the risk of hypotension.
• Neprilysin inhibition with sacubitril, combined with an angiotensin receptor blocker, increases endogenous natriuretic peptide activity and has been shown to improve survival and reduce hospitalizations in chronic heart failure.⁶
• Additional therapeutic strategies under investigation include synthetic natriuretic peptide analogs, renal-specific peptides such as urodilatin, and agents designed to prolong cGMP-mediated intracellular signaling.⁶

Recent Advances and Research Directions

• Research continues to expand the understanding of natriuretic peptide biology and its clinical applications. New biomarkers, including mid-regional pro-ANP (MR-proANP), may enhance diagnostic accuracy, particularly in complex presentations where traditional BNP measurements are confounded.⁷
• Advances in assay sensitivity and molecular techniques are improving the detection and characterization of natriuretic peptide activity. Genetic studies of NPPA and NPPB variants are providing insight into population-level differences in peptide production and cardiovascular risk.⁷
• Ongoing therapeutic development includes next-generation neprilysin inhibitors, selective NPR agonists, and novel agents that modulate downstream cGMP pathways.^6,7